Condition
Hospital Acquired Bacterial Pneumonia
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 3 (1)
P 4 (1)
Trial Status
Completed3
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07004049Phase 4Recruiting
Optimising TREATment for Severe Gram-Negative Bacterial Infections
NCT02168946Phase 3Completed
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
NCT02288234CompletedPrimary
Telavancin Observational Use Registry (TOUR)
NCT02420366Completed
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Showing all 4 trials